Ardmore Road Asset Management LP bought a new position in Docusign Inc. (NASDAQ:DOCU - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 110,000 shares of the company's stock, valued at approximately $8,954,000. Ardmore Road Asset Management LP owned approximately 0.05% of Docusign at the end of the most recent quarter.
A number of other hedge funds have also modified their holdings of the stock. Palogic Value Management L.P. raised its holdings in shares of Docusign by 2.2% in the 1st quarter. Palogic Value Management L.P. now owns 5,438 shares of the company's stock worth $443,000 after buying an additional 117 shares in the last quarter. Vident Advisory LLC boosted its position in Docusign by 26.7% in the 1st quarter. Vident Advisory LLC now owns 38,872 shares of the company's stock valued at $3,164,000 after buying an additional 8,195 shares during the last quarter. Clough Capital Partners L P bought a new position in Docusign in the 1st quarter valued at $1,114,000. Driehaus Capital Management LLC boosted its position in Docusign by 31.0% in the 1st quarter. Driehaus Capital Management LLC now owns 287,428 shares of the company's stock valued at $23,397,000 after buying an additional 67,972 shares during the last quarter. Finally, WPG Advisers LLC acquired a new position in shares of Docusign in the 1st quarter valued at $39,000. 77.64% of the stock is owned by institutional investors and hedge funds.
Docusign Stock Performance
Shares of NASDAQ DOCU traded up $1.83 during midday trading on Wednesday, reaching $75.90. The company's stock had a trading volume of 2,736,787 shares, compared to its average volume of 2,572,288. Docusign Inc. has a fifty-two week low of $54.31 and a fifty-two week high of $107.86. The business's 50 day moving average price is $75.43 and its two-hundred day moving average price is $79.56. The company has a market cap of $15.34 billion, a P/E ratio of 14.35, a P/E/G ratio of 28.61 and a beta of 1.02.
Docusign (NASDAQ:DOCU - Get Free Report) last posted its earnings results on Thursday, June 5th. The company reported $0.90 earnings per share for the quarter, topping analysts' consensus estimates of $0.81 by $0.09. The firm had revenue of $763.65 million for the quarter, compared to analysts' expectations of $748.79 million. Docusign had a net margin of 36.50% and a return on equity of 14.27%. The company's revenue was up 7.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.82 earnings per share. Docusign has set its FY 2026 guidance at EPS. Q2 2026 guidance at EPS. Sell-side analysts forecast that Docusign Inc. will post 1.17 earnings per share for the current fiscal year.
Docusign announced that its Board of Directors has authorized a stock repurchase program on Thursday, June 5th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the company to reacquire up to 6.6% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company's leadership believes its stock is undervalued.
Insider Activity at Docusign
In other Docusign news, insider Robert Chatwani sold 22,875 shares of the business's stock in a transaction on Wednesday, June 18th. The shares were sold at an average price of $74.79, for a total transaction of $1,710,821.25. Following the sale, the insider owned 72,126 shares of the company's stock, valued at approximately $5,394,303.54. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Allan C. Thygesen sold 40,000 shares of the business's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $77.51, for a total transaction of $3,100,400.00. Following the completion of the sale, the chief executive officer directly owned 143,983 shares in the company, valued at approximately $11,160,122.33. This represents a 21.74% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 78,552 shares of company stock worth $5,983,631. Corporate insiders own 1.66% of the company's stock.
Analyst Ratings Changes
DOCU has been the topic of a number of analyst reports. Wedbush cut their price target on Docusign from $100.00 to $85.00 and set a "neutral" rating on the stock in a research note on Thursday, June 12th. JPMorgan Chase & Co. dropped their price target on Docusign from $81.00 to $77.00 and set a "neutral" rating on the stock in a research note on Friday, June 6th. JMP Securities reissued a "market outperform" rating and issued a $124.00 price target on shares of Docusign in a research note on Tuesday, June 3rd. Wells Fargo & Company upgraded Docusign from an "underweight" rating to an "equal weight" rating and raised their price objective for the company from $67.00 to $80.00 in a report on Friday, June 13th. Finally, Bank of America reduced their price target on Docusign from $88.00 to $85.00 and set a "neutral" rating for the company in a report on Friday, June 6th. Four research analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $89.77.
View Our Latest Research Report on DOCU
About Docusign
(
Free Report)
DocuSign, Inc provides electronic signature solution in the United States and internationally. The company provides e-signature solution that enables sending and signing of agreements on various devices; Contract Lifecycle Management (CLM), which automates workflows across the entire agreement process; Document Generation streamlines the process of generating new, custom agreements; and Gen for Salesforce, which allows sales representatives to automatically generate agreements with a few clicks from within Salesforce.
Featured Stories
Before you consider Docusign, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Docusign wasn't on the list.
While Docusign currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
